The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: findings from the Parkinson’s Progression Markers Initiative
Objective: To determine the functional consequences of baseline anxiety symptoms and the longer-term impact of initiation of anxiety treatment in Parkinson’s disease (PD). Background: While…Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…Clinical features and phenoconversion risk in women with isolated REM sleep behavior disorder
Objective: To determine features predictive of differential phenoconversion rates in isolated REM sleep Behavior Disorder (iRBD) to a defined neurodegenerative disease (NDD). Background: iRBD is…Predictors of antidepressant and benzodiazepine treatment in Parkinson’s disease
Objective: To assess the prevalence of antidepressant and benzodiazepine (BDZ) treatment in Parkinson’s disease (PD), to analyze treatment with respect to altered mood indication, and…Implementing Systematic Screening and a Treatment Algorithm for Depression in Parkinson’s Disease
Objective: Assess the feasibility and impact of systematic depression screening and management in movement disorders centers. Background: Depression is common in Parkinson’s disease (PD) and…Potential drug-drug interactions in hospitalized patients with Parkinson’s disease from tertiary center in Serbia
Objective: The aim of this study was to identify predictors of potential drug-drug interactions in patients suffering from Parkinson’s disease.The aim of this study was…Acute functional movement disorder in a Lupus patient
Objective: Movement disorders (MD) in autoimmune diseases are uncommon. However, the initial presentation required that the clinicians characterize the clinical phenomenology. Rheumatological patients' complexity required…hUC-MSCs ameliorated CUMS-induced depression by modulating complement C3 signaling-mediated microglial polarization during astrocyte-microglia crosstalk
Objective: To demonstrate whether hUC-MSCs can benefit depressive-like behavior by altering C3/C3a-C3aR signaling to impact microglia polarization in the CUMS model. Background: Major depressive disorder (MDD) has been…Elevated nigral iron is associated with low plasma serotonin in Parkinson’s disease
Objective: The objective of this work was to determine whether plasma serotonin levels in Parkinson’s disease (PD) are related to iron levels in the brain,…Effects of Long-Term Treatment with Fluvoxamine on Non-Motor Symptoms and Neurogenesis in an Early Post-Natal Stress Rat Model of Parkinson’s Disease
Objective: To look at the long-term effects of Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), and its neuroprotection potential in a rat model of Parkinson’s…